Are you a Health Professional? Jump over to the doctors only platform. Click Here

Chemoradiotherapy improves in CNS lymphoma

Print Friendly, PDF & Email

A recent US study has been conducted to assess the role of combination therapy plus cranial irradiation in 102 newly diagnosed patients with primary CNS lymphoma (PCNSL).

The study found that: ‘58% of patients with measurable disease had a complete response to preirradiation chemotherapy and 36% had a partial (> 50%) response, for a 94% response rate. Median progression-free survival was 24.0 months and overall survival was 36.9 months. Age was an important prognostic factor; median survival was 50.4 months in patients younger than 60 and only 21.8 months in those aged 60 or older (P < .001).' The researchers concluded, ‘This is the first multicenter trial demonstrating improved survival with the combination of chemotherapy plus RT compared with previous reports of RT alone. A high-dose methotrexate-based regimen produced a high response rate before RT was administered. High-dose methotrexate combined with cranial irradiation is an effective therapeutic approach to PCNSL, but neurotoxicity is a delayed risk of this approach.’ This study has been published in the December 2002 issue of the Journal of Clinical Oncology. (Source: OMNUS Oncology)


Print Friendly, PDF & Email

Dates

Posted On: 30 December, 2002
Modified On: 3 December, 2013

Tags



Created by: myVMC